What is Mounjaro and how is it different from Ozempic and Wegovy?
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication originally developed by Eli Lilly for type 2 diabetes. Unlike Ozempic and Wegovy (which contain semaglutide and act only on GLP-1 receptors), Mounjaro is a dual agonist, it activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously.
This dual-receptor activation appears to produce stronger metabolic effects. Head-to-head trial data (SURMOUNT and SURPASS programs) consistently shows different weight-change range in trials and HbA1c reduction with tirzepatide than with semaglutide at maximum doses. For weight loss specifically, the SURMOUNT-1 trial reported average weight reduction of approximately 20% over 72 weeks at the 15mg dose, compared to roughly 15% for semaglutide 2.4mg.
In short: Mounjaro is widely considered the TGA-approved GLP-1-class medication currently available in Australia, bu. It is also the most expensive, and is not PBS-subsidised.
Why isn’t Mounjaro on the PBS?
The Pharmaceutical Benefits Advisory Committee assesses every PBS submission against clinical effectiveness and cost-effectiveness. As of 2026, Mounjaro is not listed for either indication. Reasons typically cited in PBAC outcomes for similar medications include:
- Budget impact. A drug with a large eligible population, taken long-term, at $450+/month creates substantial Federal budget exposure.
- Comparator pricing. The PBAC weighs Mounjaro against PBS-subsidised alternatives (Ozempic at $31.60/month for diabetes). To list, Mounjaro typically needs to demonstrate cost-effectiveness at an acceptable incremental price.
- Established alternatives. For T2D, multiple effective subsidised alternatives already exist (Ozempic, metformin, sulfonylureas, DPP-4 inhibitors). PBAC submissions need to demonstrate Mounjaro adds material clinical value over these.
Eli Lilly has lodged applications. Outcomes are published on the Department of Health website after each quarterly PBAC meeting. Until a listing is approved, Mounjaro remains entirely private cost.
What you’ll pay for Mounjaro in 2026
| Pathway | Monthly cost | What’s included |
|---|---|---|
| Retail pharmacy + GP | $450–$580 | Medication only; GP consult fees separate |
| Telehealth bundle | $400–$550 | Medication + consultations + coaching all-inclusive |
| Specialist (endocrinologist) | $500–$700+ | Initial specialist consult $250–$450; medication retail price |
Dose escalation costs the same per month as maintenance doses (manufacturer pricing is dose-flat). Compare your real cost in our GLP-1 switch cost calculator.
Mounjaro vs Ozempic vs Wegovy: which to choose?
If cost is the priority and you have type 2 diabetes meeting Authority Streamlined criteria, PBS-subsidised Ozempic at $31.60/month is materially cheaper than any other option, by a factor of 14. Check your PBS eligibility here.
If you don’t qualify for PBS Ozempic and are paying privately for weight loss, the comparison is:
| Drug | Cost/month (private) | Trial weight loss | Mechanism |
|---|---|---|---|
| Mounjaro (tirzepatide) | $450–$580 | ~20% (72 weeks, 15mg) | Dual GIP/GLP-1 |
| Wegovy (semaglutide 2.4mg) | $420–$530 | ~15% (68 weeks, 2.4mg) | GLP-1 only |
| Ozempic off-label (semaglutide 1mg) | $380–$450 | ~10–12% (1mg dose cap) | GLP-1 only |
Side effects and tolerability
Mounjaro's side effect profile is similar to other GLP-1 medications, predominantly gastrointestinal (nausea, vomiting, diarrhoea, constipation). Trial discontinuation rates for gastrointestinal side effects in SURMOUNT-1 were approximately 4-7% depending on dose. Slow titration (typically 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg over 5-6 months) significantly reduces side effect severity.
Less common but serious risks include pancreatitis, gallbladder disease, and (rare) medullary thyroid carcinoma, Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Your prescriber should screen for these before commencing therapy.
Realistic prescription pathway
For Australians wanting Mounjaro in 2026, the typical pathway is:
- BMI assessment + comorbidity review. Your GP confirms BMI ≥30, or ≥27 with comorbidity (typically using off-label Mounjaro for the patient who would qualify for Wegovy if it were preferred).
- Baseline blood work. HbA1c, lipid profile, liver function, renal function. Thyroid history reviewed.
- Telehealth or in-person consult. Compare bundled telehealth pricing vs your existing GP relationship; telehealth often saves $50-$100/month all-in.
- Private prescription. Filled at any Australian pharmacy. No PBS Authority involved.
- Ongoing monitoring. Reputable programmes include monthly check-ins, dose escalation review, and periodic blood work. Avoid clinics that simply ship medication without monitoring.
When PBS listing might change the picture
If Mounjaro is approved for PBS listing in the future, it would most likely be:
- Initially for type 2 diabetes only (mirroring the existing Ozempic Authority Streamlined approach)
- With strict clinical criteria (HbA1c thresholds, prior therapy requirements)
- At a substantially lower government-negotiated price than current retail
A PBS listing for weight loss (without diabetes) is unlikely in the near term given the PBAC has not yet listed Wegovy for the same indication. Watch quarterly outcomes statements for updates.
Related coverage
- Is Ozempic covered by PBS?the only GLP-1 with PBS pathway
- Is Wegovy covered by PBS?sibling answer, same PBAC concern
- How Ozempic is prescribed off-label
- Mounjaro cost hub, detailed pricing